Last reviewed · How we verify
Semaglutide 2.4 mg
At a glance
| Generic name | Semaglutide 2.4 mg |
|---|---|
| Also known as | Standard of care, Wegovy |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth (PHASE3)
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (PHASE3)
- A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (PHASE3)
- Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (PHASE2)
- A Study of a Novel Precision Medicine Approach For Obesity (PHASE4)
- The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide 2.4 mg CI brief — competitive landscape report
- Semaglutide 2.4 mg updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI